Related Experiment Videos
1Centre de référence des syndromes drépanocytaires majeurs, unité des maladies génétiques du globule rouge, CHU Henri-Mondor, AP-HP, Créteil, France; INSERM-U955, institut Mondor, université Paris-Est Créteil, team 2 Transfusion et maladies du globule rouge, laboratoire d´excellence GR-Ex, Créteil, France.
Summary
Anemia is common in sickle cell disease (SCD). Transfusions manage SCD complications, but strategies now consider post-transfusion hemolysis and transfusion risk scores for safer patient care.
Area of Science:
- Hematology
- Internal Medicine
- Genetics
Context:
- Anemia is a frequent and significant complication in sickle cell disease (SCD).
- Investigating anemia in SCD requires consideration of both disease-specific and general causes.
- Transfusion therapy is a cornerstone in managing SCD, addressing acute and chronic complications.
Purpose:
- To highlight the importance of investigating anemia in sickle cell disease.
- To discuss the role of transfusions and exchange transfusions in SCD management.
- To emphasize the evolving transfusion strategies considering post-transfusion hemolysis and risk stratification.
Summary:
- Worsening anemia is prevalent in sickle cell disease (SCD), necessitating comprehensive etiological investigation.
- Transfusions and exchange transfusions are critical interventions for acute and chronic SCD complications, including prevention.
- Current transfusion strategies incorporate awareness of post-transfusion hemolysis and utilize transfusion risk scores.
- Effective management requires robust collaboration among specialized SCD centers, blood services, and inpatient units.
Impact:
- Modified transfusion strategies improve patient outcomes by mitigating risks like post-transfusion hemolysis.
- Risk-stratified transfusion approaches enhance the safety and efficacy of managing anemia in SCD.
- Interdisciplinary collaboration is essential for optimal decision-making in transfusion therapy for SCD patients.